Compare Check Point Software Technologies Ltd (CHKP) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs Twist Bioscience Corp — how do they compare? Check Point Software Technologies Ltd trades at $132.94 (market cap $13.97B), while Twist Bioscience Corp trades at $92.62 (market cap $5.77B). The key difference: Check Point Software Technologies Ltd is far larger — about 2.4× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | TWST | |
|---|---|---|
Market Cap | $13.97B | $5.77B |
Sector | Technology | Health |
52-Week High | $223.00 | $102.88 |
52-Week Low | $112.47 | $24.16 |
Enterprise Value | $13.17B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHKP trades at $134.32, up 1.99% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 38.37% net income margin and trades at a P/E of 13.82. Recent news highlights AI security partnerships and upcoming Q2 2026 earnings on July 30, 2026.
Outlook is mixed: analyst consensus targets $148.43 (10.5% upside) with 46% buy ratings, but technicals and insider sales pose risks. Key catalysts include AI integration progress and earnings results, while competition and sector volatility remain headwinds.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
